CS273139B1 - Method of pharmaceutical agent production for intranasal feed - Google Patents

Method of pharmaceutical agent production for intranasal feed Download PDF

Info

Publication number
CS273139B1
CS273139B1 CS930487A CS930487A CS273139B1 CS 273139 B1 CS273139 B1 CS 273139B1 CS 930487 A CS930487 A CS 930487A CS 930487 A CS930487 A CS 930487A CS 273139 B1 CS273139 B1 CS 273139B1
Authority
CS
Czechoslovakia
Prior art keywords
composition according
oil
phospholipid
composition
insulin
Prior art date
Application number
CS930487A
Other languages
Czech (cs)
English (en)
Other versions
CS930487A1 (en
Inventor
Philip E Hansen
Anders R Sorensen
Original Assignee
Philip E Hansen
Anders R Sorensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK604286A external-priority patent/DK604286D0/da
Priority claimed from DK370087A external-priority patent/DK370087D0/da
Application filed by Philip E Hansen, Anders R Sorensen filed Critical Philip E Hansen
Publication of CS930487A1 publication Critical patent/CS930487A1/cs
Publication of CS273139B1 publication Critical patent/CS273139B1/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CS930487A 1986-12-16 1987-12-16 Method of pharmaceutical agent production for intranasal feed CS273139B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK604286A DK604286D0 (da) 1986-12-16 1986-12-16 Praeparat
DK370087A DK370087D0 (da) 1987-07-16 1987-07-16 Produkt med forbedrede egenskaber

Publications (2)

Publication Number Publication Date
CS930487A1 CS930487A1 (en) 1990-07-12
CS273139B1 true CS273139B1 (en) 1991-03-12

Family

ID=26067181

Family Applications (1)

Application Number Title Priority Date Filing Date
CS930487A CS273139B1 (en) 1986-12-16 1987-12-16 Method of pharmaceutical agent production for intranasal feed

Country Status (22)

Country Link
EP (1) EP0272097B1 (ja)
JP (1) JPH0768149B2 (ja)
KR (1) KR890700036A (ja)
CN (1) CN1034105C (ja)
AT (1) ATE79039T1 (ja)
AU (1) AU606121B2 (ja)
CA (1) CA1326210C (ja)
CS (1) CS273139B1 (ja)
DE (1) DE3780925T2 (ja)
ES (1) ES2044957T3 (ja)
FI (1) FI94024C (ja)
GR (1) GR3005381T3 (ja)
HU (1) HU209247B (ja)
IE (1) IE61110B1 (ja)
IL (1) IL84835A (ja)
MX (1) MX9203640A (ja)
NO (1) NO175566C (ja)
NZ (1) NZ222907A (ja)
PT (1) PT86370B (ja)
RU (1) RU1837869C (ja)
WO (1) WO1988004556A1 (ja)
YU (1) YU46978B (ja)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
ES2061688T3 (es) * 1987-11-13 1994-12-16 Smithkline Beecham Farma Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
JPH05500203A (ja) * 1989-02-17 1993-01-21 ザ　リポソーム　カンパニー，インコーポレイテッド 鼻腔内搬送用及び局所適用脂質賦形剤
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5725871A (en) * 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
DE4214953C2 (de) * 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
DE4218291A1 (de) * 1992-06-03 1993-12-09 Mattern Et Partner Pharmazeuti Dosierspray für pernasale Applikation
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
ATE223202T1 (de) * 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
RU2155604C2 (ru) * 1998-01-29 2000-09-10 МНПП "Экоспектр" Лецитиновый органогель
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
DE69942305D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
ATE251465T1 (de) 1998-07-31 2003-10-15 Novo Nordisk As In-vitro stimulation von beta zellen vermehrung
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6849263B2 (en) 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US7087215B2 (en) 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
ES2253353T3 (es) 2000-03-08 2006-06-01 Novo Nordisk A/S Reduccion del colesterol serico.
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
JP2004535432A (ja) * 2001-06-22 2004-11-25 ベントレー ファーマシューティカルズ インコーポレイテッド 医薬組成物
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
AU2002352836B2 (en) 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
GB0205327D0 (en) * 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
DK2275439T3 (da) 2003-08-05 2014-05-12 Novo Nordisk As Hidtil ukendte insulinderivater
BR122019021416A2 (ja) 2003-09-19 2019-12-21
EP1734938B1 (en) 2004-03-26 2012-06-20 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
CN1299770C (zh) * 2004-05-31 2007-02-14 刘近周 多功能鼻腔和鼻窦洁疗液
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
EP2015770B1 (en) 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
US9150633B2 (en) 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
SG189682A1 (en) 2008-03-31 2013-05-31 Glaxo Group Ltd Drug fusions and conjugates
CN102065903B (zh) 2008-04-01 2015-02-18 诺沃-诺迪斯克有限公司 胰岛素清蛋白缀合物
US8277781B2 (en) 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8551454B2 (en) 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
CN104127880A (zh) 2009-03-27 2014-11-05 葛兰素集团有限公司 药用融合体和缀合物
CN104147611A (zh) 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
EP2788027A2 (en) 2011-12-09 2014-10-15 Novo Nordisk A/S Glp-1 agonists
EP2844274B1 (en) 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
US20210369799A1 (en) 2018-11-04 2021-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nasal compositions and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594476A (en) * 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
GB1527605A (en) * 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
DE3323389A1 (de) * 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
GB8327330D0 (en) * 1983-10-12 1983-11-16 Parsons W J Membrane analogue emulsions
WO1985005029A1 (en) * 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
IL78425A (en) * 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
IT1187743B (it) * 1985-09-26 1987-12-23 Prodotti Formenti Srl Composizioni farmaceutiche a base di destrorfano per applicazione instranasale

Also Published As

Publication number Publication date
FI94024B (fi) 1995-03-31
EP0272097A3 (en) 1988-08-24
CS930487A1 (en) 1990-07-12
AU606121B2 (en) 1991-01-31
YU46978B (sh) 1994-09-09
IL84835A0 (en) 1988-06-30
IE873408L (en) 1988-06-16
NZ222907A (en) 1990-08-28
DE3780925T2 (de) 1992-12-24
HU209247B (en) 1994-04-28
CN1034105C (zh) 1997-02-26
HUT57592A (en) 1991-12-30
IL84835A (en) 1994-01-25
AU1085888A (en) 1988-07-15
NO883627D0 (no) 1988-08-15
FI883783A0 (fi) 1988-08-15
IE61110B1 (en) 1994-10-05
WO1988004556A1 (en) 1988-06-30
NO175566B (no) 1994-07-25
FI94024C (fi) 1995-07-10
GR3005381T3 (ja) 1993-05-24
ES2044957T3 (es) 1994-01-16
RU1837869C (ru) 1993-08-30
KR890700036A (ko) 1989-03-02
JPH0768149B2 (ja) 1995-07-26
FI883783L (fi) 1988-08-15
CA1326210C (en) 1994-01-18
NO175566C (no) 1994-11-02
JPH01501550A (ja) 1989-06-01
ATE79039T1 (de) 1992-08-15
MX9203640A (es) 1992-09-01
CN87108340A (zh) 1988-07-13
EP0272097B1 (en) 1992-08-05
YU228487A (en) 1988-12-31
DE3780925D1 (de) 1992-09-10
PT86370A (en) 1988-01-01
NO883627L (no) 1988-08-15
PT86370B (pt) 1990-11-20
EP0272097A2 (en) 1988-06-22

Similar Documents

Publication Publication Date Title
CS273139B1 (en) Method of pharmaceutical agent production for intranasal feed
US5179079A (en) Nasal formulation and intranasal administration therewith
EP0128831B1 (en) Drug administration
KR100217258B1 (ko) 경비조성물
AU617157B2 (en) Intravaginal delivery of biologically active polypeptides
US4959358A (en) Drug administration
JP4785960B2 (ja) 医薬組成物
EP0566135A1 (en) Transmucosal composition comprising a peptide and a cytidine derivative
WO1993018785A1 (en) Novel medicament
EP0308181A1 (en) Trans-mucosal delivery formulations and a method for preparation thereof
WO2000074736A9 (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
SA95160483B1 (ar) صيغ رذاذية aerosol formuation من البيبتيدات peptides والبروتينات proteins
JPH01308235A (ja) ヒト成長ホルモン経鼻剤
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
JPH07165614A (ja) 経鼻組成物及びそれを含有する経鼻製剤
SI8712284A (sl) Pripravki za nazalno uporabo in postopki za njihovo pridobivanje
JPH06199681A (ja) 生理活性ペプチド組成物